Severe Lenalidomide-Associated Hyperbilirubinemia. (Record no. 11546)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01832nam a22003377a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 230411s20232023 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2168-8184 |
| 024 ## - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.7759/cureus.34408 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER | |
| Standard number or code | PMC9977541 [pmc] |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| PMID | 36874759 |
| 245 ## - TITLE STATEMENT | |
| Title | Severe Lenalidomide-Associated Hyperbilirubinemia. |
| 251 ## - Source | |
| Source | Cureus. 15(1):e34408, 2023 Jan. |
| 252 ## - Abbreviated Source | |
| Abbreviated source | Cureus. 15(1):e34408, 2023 Jan. |
| 253 ## - Journal Name | |
| Journal name | Cureus |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Year | 2023 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Manufacturer | FY2023 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Publication date | 2023 Jan |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
| Publication status | epublish |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
| Medline status | PubMed-not-MEDLINE |
| 266 ## - Date added to catalog | |
| Date added to catalog | 2023-04-11 |
| 520 ## - SUMMARY, ETC. | |
| Abstract | Immunomodulatory drugs (IMids), such as thalidomide and lenalidomide, are used to treat plasma cell neoplasms and B-cell malignancies. We present a case of severe direct hyperbilirubinemia in a patient taking lenalidomide-based therapy for plasmacytoma. Imaging was unrevealing, and liver biopsy showed only mild sinusoidal dilation. Roussel Uclaf Causality Assessment (RUCAM) score was 6, indicating lenalidomide was a probable cause of the injury. To our knowledge, this is the highest reported direct bilirubin regarding lenalidomide drug-induced liver injury (DILI), with a peak bilirubin of 41mg/dL. While a clear pathophysiology was not identified, this case provides important considerations regarding lenalidomide safety. Copyright © 2023, Gildea et al. |
| 546 ## - LANGUAGE NOTE | |
| Language note | English |
| 656 ## - INDEX TERM--OCCUPATION | |
| Department | Internal Medicine Residency |
| 656 ## - INDEX TERM--OCCUPATION | |
| Department | MedStar Georgetown University Hospital/MedStar Washington Hospital Center |
| 657 ## - INDEX TERM--FUNCTION | |
| Medline publication type | Case Reports |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Local Authors | Gildea, Daniel |
| Institution Code | MGUH |
| Program | Internal Medicine Residency |
| Degree | MD |
| Resident year | Resident PGY 2 |
| 790 ## - Authors | |
| All authors | Gildea DT, Roswarski JL |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| DOI | <a href="https://dx.doi.org/10.7759/cureus.34408">https://dx.doi.org/10.7759/cureus.34408</a> |
| Public note | https://dx.doi.org/10.7759/cureus.34408 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Journal Article |
| Item type description | Article |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MedStar Authors Catalog | MedStar Authors Catalog | 04/11/2023 | 04/11/2023 | 04/11/2023 | Journal Article |